424B3 - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

424B3 - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

10-Q - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

SCHEDULE 13G/A - ALLURION TECHNOLOGIES, INC. (0001964979) (Subject)

8-K - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

EFFECT - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

S-3 - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

424B3 - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

424B3 - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

SCHEDULE 13D/A - ALLURION TECHNOLOGIES, INC. (0001964979) (Subject)

Findings from two abstracts presented at the American Society for Metabolic & Bariatric Surgery (ASMBS) 2025 Annual Meeting reinforce the role of the AI-powered Allurion Program in delivering metabolically healthy weight loss Real-world experience in nearly 20,000 patients with the Allurion Program confirms significant fat loss while increasing lean body and muscle mass In one of the longest real-world studies of its kind, patients who followed the Allurion Program for four years maintained, on average, 89% of the weight lost during balloon therapy Allurion Technologies, Inc. (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today presented two new abstracts at the Amer

Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced that Dr. Shantanu Gaur, Founder and Chief Executive Officer, will present at the upcoming Jefferies Global Healthcare Conference in New York. The live presentation will take place on Wednesday, June 4 at 3:45 p.m. ET. A webcast of the presentation will be available in the Events & Presentations section of Allurion's investor relations website. About Allurion Allurion is a pioneer in metabolically healthy weight loss. The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world's first and only swallowable, proced

In 1,962 patients treated in France with the Allurion Program, muscle mass as a percentage of total body weight increased, on average, by 6.6% and fat mass decreased, on average, by 11% Company announces that shipments to France have resumed, and patient treatments are expected to resume next month Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced the presentation of a study at the Societe Francaise et Francophone de Chiurgie de l'Obesite et des Maladies Metaboliques (SOFFCO.MM) meeting in Saint-Etienne, France, May 22-23, 2025. The study, entitled "The Swallowable Gastric Balloon Program with AI Powe

Allurion Technologies, Inc. (NYSE:ALUR) ("Allurion" or the "Company"), a pioneer in metabolically healthy weight loss, today announced its financial results for the first quarter and provided a business update. Recent Company Highlights and Outlook Maintaining 2025 revenue guidance of approximately $30 million with a reduction of approximately 50% in operating expenses compared to 2024 First quarter revenue of $5.6 million and operating expenses of $11.4 million, a 37% decrease in operating expenses compared to prior year; adjusted operating expenses of $10.1 million, a 45% decrease compared to prior year Net operating loss of $7.3 million, a 36% reduction compared to prior year; adj

Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE:ALUR), a company dedicated to ending obesity, today announced that it will report financial results for the first quarter 2025 on Wednesday, May 14, 2025. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET. To access the conference call by telephone, please dial (888) 330-3417 (domestic) or +1 646 960 0804 (international) and use Conference ID 1905455. To listen to the conference call via live audio webcast, please visit the Events section of Allurion's Investor Relations website at Allurion - Events & Presentations. A replay of the conferenc

Meeting to Now be Held on Thursday, April 10, 2025 at 12:00 pm Via Live Audio Webcast Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE:ALUR), a company dedicated to ending obesity, today announced that its Special Meeting of Stockholders (the "Special Meeting"), originally scheduled for Friday, April 4, 2025, has been postponed. The Special Meeting is now scheduled to be held on Thursday, April 10, 2025 at 12:00 p.m. (Eastern Time) and will still be held virtually via live audio webcast at www.virtualshareholdermeeting.com/ALUR2025SM. The record date for the Special Meeting, March 14, 2025, remains unchanged and applies to the postponed Special Meeting. The Special Meeting

Allurion Technologies, Inc. (NYSE:ALUR) ("Allurion" or the "Company"), a company dedicated to ending obesity, today announced its financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update. Recent Company Highlights and Outlook Reported initial data on the combination of the Allurion Program with low-dose GLP-1s showing optimization of muscle mass and GLP-1 adherence and announced plans to perform additional prospective studies on the combination approach Fourth quarter 2024 revenue of $5.6 million and full year revenue of $32.1 million, consistent with preannouncement on January 14, 2025 Fourth quarter 2024 operating expenses of $19

Average Total Weight Loss of 20% With 15% Increase in Lean Body Mass After 8 Months of Combined Therapy Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE:ALUR), a company dedicated to ending obesity, today announced initial results on the combination of the Allurion Program with low-dose GLP-1 therapy to optimize muscle mass and GLP-1 adherence. 52 patients treated with the Allurion Balloon were started on 0.25mg semaglutide after completing their first month of balloon therapy. The dose of semaglutide was increased to no greater than 1.0mg over the subsequent 6 months. After 8 months of this combination approach, average total body weight loss was 20.3%, and lean body mass

Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE:ALUR), a company dedicated to ending obesity, today announced that it will report financial results for the fourth quarter 2024 on Wednesday, March 26, 2025. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET. To access the conference call by telephone, please dial (888) 330-3417 (domestic) or +1 646 960 0804 (international) and use Conference ID 1905455. To listen to the conference call via live audio webcast, please visit the Events section of Allurion's Investor Relations website at Allurion - Events & Presentations. A replay of the confer

Patent portfolio now exceeds 60 issued patents globally Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE:ALUR), a company dedicated to ending obesity, today announced that it has received two Issue Notifications from the U.S. Patent and Trademark Office (USPTO) dated February 19, 2025 for U.S. Patent No. 12,246,163 titled "Automatic-Sealing Balloon-Filling Catheter System" and U.S. Patent No. 12,245,962 titled "Balloon Sealing and Fill Valve". These patents, both of which are scheduled to issue on March 11, 2025, provide additional claims for an enhanced, next-generation version of Allurion's proprietary Balloon technology for the treatment of obesity that includes an enhanc

4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

3 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

3 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

3 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

4/A - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

Chardan Capital Markets downgraded Allurion Technologies from Buy to Neutral

TD Cowen initiated coverage of Allurion Technologies with a rating of Buy and set a new price target of $2.00

ROTH MKM initiated coverage of Allurion Technologies with a rating of Buy and set a new price target of $2.00

Jefferies initiated coverage of Allurion Technologies with a rating of Buy and set a new price target of $5.00

4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)